Stockreport

NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan

NanoVibronix, Inc.  (NAOV) 
NASDAQ:AMEX Investor Relations: otcmarkets.com/stock/naov/profile
PDF Research expected to advance to ‘Full Study’ phase in 2025 ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device compan [Read more]